Thus, our observation that CPT1A repression is critical for ccRCC growth identifies a tumor-specific metabolic adaptation of renal cancer and supports the concept that limiting FA availability by increasing oxidation could have clinical potential9. The gene discussed is CPT1A; the disease is renal carcinoma.